Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc. (Kiora) is a clinical-stage biotech company focusing on novel therapeutics for the treatment of retinal diseases. Publicly traded on the NASDAQ under KPRX, our mission is to help patients improve and/or restore vision. Our product pipeline includes KIO-301, a promising small molecule with the potential to restore vision in patients with inherited or age-related retinal degeneration, and KIO-104, a small molecule DHODH inhibitor that treats retinal inflammation.